10月17日，药捷安康-B盘初涨幅扩大至逾30%，成交额超7亿港元，该股近两个交易日累涨95%。
日前，药物临床试验登记与信息公示平台数据显示，南京药捷安康生物科技有限公司的一项在健康参与者中评价多剂量伊曲康唑或利福平或艾司奥美拉唑对单剂量TT-00420药代动力学影响的单中心、开放标签、固定序列、非随机、药物相互作用的I期临床研究已启动。临床试验登记号为CTR20254045，首次公示信息日期为2025年10月11日。
据悉，TT - 00420片为化学药物，适应症为晚期或转移性胆管癌或晚期实体瘤等。胆管癌是指源于肝外胆管包括肝门区至胆总管下端的胆管的恶性肿瘤，早期症状不明显，后期可出现黄疸、腹痛等。晚期实体瘤则是多种恶性肿瘤进展到晚期的统称，诊断依靠影像学及病理检查。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
